Douglas B. Johnson, MD, MSCI, on Updates on the Treatment Landscape in Cutaneous Melanoma

Posted: Monday, May 13, 2024

Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, reviews the role of neoadjuvant therapy in patients with operable advanced or metastatic cutaneous melanoma, key data on perioperative vs adjuvant treatments, and selection of combination regimens vs monotherapy. He also describes the clinical trial data behind using the novel strategy of tumor-infiltrating lymphocytes.

---